While previous reports showed worse outcomes in patients with advanced cancer who developed significant weight loss [24, 25], we postulate that the weight loss observed in our patient population may be an on-target toxicity of everolimus and mTOR inhibitors, rather than expression of tumour-associated cachexia. Here, MTOR is linked to cancer.